MCID: SRT004
MIFTS: 47

Serotonin Syndrome

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Serotonin Syndrome

MalaCards integrated aliases for Serotonin Syndrome:

Name: Serotonin Syndrome 58 54 17
Malignant Carcinoid Syndrome 71
Serotonergic Syndrome 58
Serotonin Toxidrome 58
Serotonin Toxicity 58
Serotonin Storm 58

Characteristics:

Orphanet epidemiological data:

58
serotonin syndrome
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

MESH via Orphanet 44 D020230
UMLS via Orphanet 72 C0699828
Orphanet 58 ORPHA43116
UMLS 71 C0024586

Summaries for Serotonin Syndrome

MalaCards based summary : Serotonin Syndrome, also known as malignant carcinoid syndrome, is related to neuroleptic malignant syndrome and depression. An important gene associated with Serotonin Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Rasagiline and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Serotonin syndrome (SS) is a group of symptoms that may occur with the use of certain serotonergic... more...

Related Diseases for Serotonin Syndrome

Diseases related to Serotonin Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 neuroleptic malignant syndrome 31.0 HTR3A HTR2A HTR1A CYP2D6
2 depression 30.5 SLC6A4 MAOA HTR2A HTR1A
3 fibromyalgia 30.1 SLC6A4 HTR3A HTR2A HTR1A
4 cocaine abuse 29.9 SLC6A4 MAOB HTR3A
5 hepatic encephalopathy 29.8 SST MAOB MAOA
6 mental depression 29.8 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
7 tic disorder 29.8 SLC6A4 MAOA HTR2A HTR1A
8 generalized anxiety disorder 29.7 SLC6A4 MAOA HTR3A HTR2A HTR1A CYP2D6
9 hyperprolactinemia 29.7 SST HTR2A GHRH
10 bipolar disorder 29.6 SST SLC6A4 MAOA HTR3A HTR2A HTR1A
11 mood disorder 29.5 SLC6A4 MAOB MAOA HTR3A HTR2A HTR1A
12 post-traumatic stress disorder 29.5 SLC6A4 MAOB MAOA HTR2A HTR1A
13 somatoform disorder 29.4 TAC1 SLC6A4 HTR3A
14 endogenous depression 29.3 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
15 small cell cancer of the lung 29.2 SST GAST CHGA
16 attention deficit-hyperactivity disorder 29.1 SLC6A4 OXT MAOB MAOA HTR2A HTR1A
17 obsessive-compulsive disorder 29.0 SST SLC6A4 OXT MAOB MAOA HTR3A
18 parkinson disease, late-onset 28.8 TAC1 SLC6A4 MAOB MAOA HTR3A HTR2A
19 panic disorder 28.7 TAC1 SLC6A4 MAOA HTR3A HTR2A HTR1A
20 anorexia nervosa 28.6 SLC6A4 PYY OXT MAOA HTR2A HTR1A
21 migraine with or without aura 1 28.3 TAC1 SLC6A4 OXT MAOB MAOA HTR3A
22 major depressive disorder 28.2 TAC1 SST SLC6A4 OXT MAOB MAOA
23 carcinoid syndrome 28.0 SST PYY MEN1 IFNA2 HTR3A GHRH
24 anxiety 27.8 TAC1 SLC6A4 OXT MAOB MAOA HTR3A
25 diarrhea 27.2 TAC1 SST SLC6A4 PYY MEN1 IFNA2
26 constipation 27.2 TAC1 SST SLC6A4 PYY HTR3A HTR2A
27 tremor 10.5
28 myoclonus 10.5
29 tardive dyskinesia 10.5 HTR2A CYP2D6
30 hypertrophy of tongue papillae 10.4 CYP3A4 CYP2D6
31 pedophilia 10.4 OXT MAOA
32 alcoholic psychosis 10.4 SLC6A4 HTR2A
33 barbiturate abuse 10.4 MAOB MAOA
34 drug psychosis 10.4 HTR2A HTR1A
35 drug-induced mental disorder 10.4 HTR2A HTR1A
36 delusional disorder 10.4 HTR2A HTR1A CYP2D6
37 duodenal benign neoplasm 10.4 SST CHGA
38 ampulla of vater neoplasm 10.4 SST CHGA
39 kleptomania 10.4 SLC6A4 MAOA HTR1A
40 hypoactive sexual desire disorder 10.4 OXT HTR2A HTR1A
41 carotid body cancer 10.3 SST CHGA
42 gastric hemangioma 10.3 SST CHGA
43 adjustment disorder 10.3 SLC6A4 HTR2A HTR1A
44 vaginal adenoma 10.3 OXT CHGA
45 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.3
46 inhibited male orgasm 10.3 SLC6A4 OXT HTR1A
47 conidiobolomycosis 10.3 CYP3A4 CYP2D6
48 bipolar i disorder 10.3 SLC6A4 HTR2A HTR1A
49 dissociative disorder 10.3 SLC6A4 OXT HTR2A
50 autoimmune atrophic gastritis 10.3 GAST CHGA

Comorbidity relations with Serotonin Syndrome via Phenotypic Disease Network (PDN):


Intestinal Obstruction

Graphical network of the top 20 diseases related to Serotonin Syndrome:



Diseases related to Serotonin Syndrome

Symptoms & Phenotypes for Serotonin Syndrome

GenomeRNAi Phenotypes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.78 MAOA MEN1
2 Decreased viability GR00240-S-1 9.78 SST
3 Decreased viability GR00249-S 9.78 MAOB SLC6A4
4 Decreased viability GR00381-A-1 9.78 CYP2D6 HTR1A HTR3A PYY SLC6A4
5 Decreased viability GR00381-A-3 9.78 HTR1A HTR3A SLC6A4
6 Decreased viability GR00386-A-1 9.78 NOTCH1
7 Decreased viability GR00402-S-2 9.78 CGB3 CYP2D6 GHRH HTR1A HTR3A PYY

MGI Mouse Phenotypes related to Serotonin Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 GHRH HTR1A HTR2A HTR3A MAOA MAOB
2 endocrine/exocrine gland MP:0005379 9.81 CHGA GAST GHRH HTR2A HTR3A MEN1
3 digestive/alimentary MP:0005381 9.8 GAST HTR2A MEN1 NOTCH1 OXT SLC6A4
4 homeostasis/metabolism MP:0005376 9.8 CHGA GAST GHRH HTR1A HTR3A MAOA
5 nervous system MP:0003631 9.44 CHGA GHRH HTR1A HTR3A MAOA MAOB

Drugs & Therapeutics for Serotonin Syndrome

Drugs for Serotonin Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4 136236-51-6 3052776
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
10
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
11
Tapentadol Approved Phase 4 175591-23-8 9838022
12
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
13
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
14
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15 Pharmaceutical Solutions Phase 4
16 Epinephryl borate Phase 4
17 diuretics Phase 4
18 Hormones Phase 4
19 Psychotropic Drugs Phase 4
20 Calcium, Dietary Phase 4
21 Narcotics Phase 4
22 Analgesics, Opioid Phase 4
23 Analgesics Phase 4
24 Anesthetics Phase 4
25 Citrate Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 Anesthetics, Dissociative Phase 4
28 Anesthetics, General Phase 4
29 Anesthetics, Intravenous Phase 4
30 Adrenergic Agents Phase 4
31 Anti-Anxiety Agents Phase 4
32 Anticonvulsants Phase 4
33 calcium channel blockers Phase 4
34 Dopamine agonists Phase 4
35 Protective Agents Phase 4
36 Hypnotics and Sedatives Phase 4
37 S 20098 Phase 4
38 Antioxidants Phase 4
39 Antiparkinson Agents Phase 4
40 Neurotransmitter Agents Phase 4
41 Dopamine Agents Phase 4
42
Calcium Nutraceutical Phase 4 7440-70-2 271
43
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
44
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
45
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
46
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
47
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
48
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 6857599 5310940 9887054
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
50 Pancreatic Polypeptide Investigational Phase 2, Phase 3 59763-91-6

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study Completed NCT03843944 Phase 4 Safinamide
2 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
3 A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department Recruiting NCT03959852 Phase 4 Fentanyl;Ketamine
4 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
5 A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease Not yet recruiting NCT03977441 Phase 4 Agomelatine or PIacebo
6 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
7 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
8 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
9 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
10 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
12 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
13 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Terminated NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
14 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Withdrawn NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
15 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
16 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
17 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
18 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
19 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
20 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
21 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
22 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
23 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
24 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
25 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
26 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
27 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
28 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
29 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
30 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
31 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
32 Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET Recruiting NCT03453489 Phase 2 Telotristat Etiprate
33 A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET). Recruiting NCT03722511 Phase 2
34 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
35 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
36 Phase II Randomised Trial to Assess Progression of Carcinoid Heart Disease in Patients Treated With Lutathera Therapy Compared to Best Supportive Care. Not yet recruiting NCT04039516 Phase 2 Lutathera
37 Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
38 Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
39 Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
40 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
41 Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
42 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
43 A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
44 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
45 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
46 Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
47 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
48 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
49 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
50 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride

Search NIH Clinical Center for Serotonin Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Genetic Tests for Serotonin Syndrome

Anatomical Context for Serotonin Syndrome

MalaCards organs/tissues related to Serotonin Syndrome:

40
Heart, Brain, Liver, Bone, Small Intestine, Breast, Colon

Publications for Serotonin Syndrome

Articles related to Serotonin Syndrome:

(show top 50) (show all 1301)
# Title Authors PMID Year
1
Is tapentadol an advance on tramadol? 54 61
20092221 2009
2
[Serotonin syndrome associated with linezolid use: a case report]. 61 54
20013432 2009
3
Serotonin syndrome: a complex but easily avoidable condition. 54 61
18433663 2008
4
5-Hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamus mediate oxytocin and adrenocorticotropin hormone release and some behavioral components of the serotonin syndrome. 61 54
15743927 2005
5
The serotonin syndrome. 61 54
15635814 2004
6
Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. 54 61
11889332 2002
7
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. 54 61
10090793 1999
8
Treatment of the serotonin syndrome with cyproheptadine. 54 61
9696181 1998
9
Serotonin syndrome and drug combinations: focus on MAOI and RIMA. 54 61
9224903 1997
10
Serotonin syndrome complicating migraine pharmacotherapy. 54 61
8869767 1996
11
[Serotonin syndrome in acute poisoning with antidepressive agents]. 61 54
9033760 1996
12
Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors. 54 61
1387164 1992
13
A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities. 61
32057547 2020
14
Underlying Serotonin Syndrome, Masked by Community-Acquired Pneumonia and Myocardial Ischemia. 61
32503963 2020
15
Deep brain stimulation as a possible treatment of hyperthermia in patients with serotonin syndrome. 61
32251940 2020
16
Serotonin Syndrome Following Terbutaline Administration in a Heart Transplant Patient on Multiple Inotropic Agents: A Case Report. 61
32560969 2020
17
Quality of Evidence Supporting Major Psychotropic Drug-Drug Interaction Warnings: A Systematic Literature Review. 61
32107798 2020
18
Development of severe serotonin syndrome from acute ingestion of vilazodone without co-ingestion. 61
31902699 2020
19
Knowledge, Attitude and Practice (KAP) Study on serotonin syndrome among psychiatrists. 61
32466831 2020
20
Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department. 61
32426664 2020
21
Iatrogenesis and neurological manifestations in the elderly. 61
32389421 2020
22
Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents: A Case Report. 61
32217863 2020
23
[Serotonin syndrome shortly after the administration of low-dose mirtazapine]. 61
32400384 2020
24
Vilazodone poisoning: a systematic review. 61
31777303 2020
25
Hypermetabolic Syndrome and Dyskinesia After Neurologic Surgery for Labrune Syndrome: A Case Report. 61
32371820 2020
26
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. 61
32531579 2020
27
Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. 61
32415846 2020
28
[Drug-drug Interactions in Intensive Care]. 61
32434261 2020
29
Increased Brain Serotonin Rather Than Increased Blood Acetaldehyde as a Common Denominator Behind Alleged Disulfiram-Like Reactions. 61
32292075 2020
30
Triple quadrupole-mass spectrometry protocols for the analysis of NBOMes and NBOHs in blotter papers. 61
32086005 2020
31
A preliminary study of rapid-fire high-throughput metabolite analysis using nano-flow injection/Q-TOFMS. 61
32328692 2020
32
Serotonin toxicity from isolated bupropion overdoses. 61
32285711 2020
33
Triptan and ergotamine overdoses in the United States: Analysis of the National Poison Data System. 61
31792093 2020
34
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. 61
31030620 2020
35
Intrathecal Baclofen Overdose With Paradoxical Autonomic Features Mimicking Withdrawal. 61
32204996 2020
36
Linezolid and fentanyl: An underrecognized drug-to-drug interaction. 61
32304579 2020
37
Multivisceral Failure in a Context of Serotonin Syndrome Induced by MDMA: The Investigation of a Unique and Nationwide Network. 61
31188157 2020
38
A Case of Serotonin Syndrome in the Setting of Dextromethorphan-Based Cough Medicine, Tramadol, and Multiple Antidepressants. 61
32141719 2020
39
Severe serotonin syndrome caused by an interaction between an antidepressant and a cough syrup. 61
32192714 2020
40
Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants. 61
31913969 2020
41
Behavioral effects of citalopram, tramadol, and binary mixture in zebrafish (Danio rerio) larvae. 61
31425864 2020
42
Use of Cyproheptadine for the Treatment of Serotonin Syndrome: A Case Series. 61
31860612 2020
43
Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome. 61
32064090 2020
44
Serotonin Syndrome Developing Immediately after the Initiation of Low-Dose Methadone Therapy: A Case Report. 61
32308591 2020
45
Serotonin Syndrome Presenting as a Posterior Reversible Encephalopathy Syndrome. 61
32231545 2020
46
Adolescent Polypharmacy and Serotonin Syndrome. 61
31934921 2020
47
Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial. 61
31890684 2019
48
Black Seed Oil and Perioperative Serotonin Syndrome: A Case Report. 61
31577540 2019
49
Serotonin Syndrome in the Emergency Department. 61
31938599 2019
50
Oral fenugreek seed consumption and serotonin syndrome. 61
31379190 2019

Variations for Serotonin Syndrome

Expression for Serotonin Syndrome

Search GEO for disease gene expression data for Serotonin Syndrome.

Pathways for Serotonin Syndrome

Pathways related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 TAC1 SSTR1 SST PYY OXT HTR2A
2 12 SSTR1 SST OXT HTR1A
3
Show member pathways
11.7 SLC6A4 CYP3A4 CYP2D6
4
Show member pathways
11.62 MAOB MAOA CYP3A4
5 11.56 SLC6A4 MAOB MAOA HTR3A HTR2A HTR1A
6 11.43 TAC1 SSTR1 SST SLC6A4 MAOA HTR3A
7 11 SLC6A4 MAOA HTR3A HTR2A HTR1A
8
Show member pathways
10.92 SLC6A4 MAOB MAOA HTR1A
9
Show member pathways
10.73 MAOB MAOA
10
Show member pathways
10.7 HTR3A CYP3A4 CYP2D6
11 10.64 MAOB MAOA
12
Show member pathways
10.57 MAOB MAOA
13 10.36 MAOA CYP2D6

GO Terms for Serotonin Syndrome

Cellular components related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.8 TAC1 SST SLC6A4 HTR3A HTR2A HTR1A
2 extracellular region GO:0005576 9.65 TAC1 SST PYY OXT NOTCH1 IFNA2
3 integral component of presynaptic membrane GO:0099056 9.43 SLC6A4 HTR3A HTR2A
4 integral component of postsynaptic membrane GO:0099055 9.33 SLC6A4 HTR3A HTR2A
5 extracellular space GO:0005615 9.28 TAC1 SST PYY OXT IFNA2 GHRH

Biological processes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 SST SLC6A4 MAOB HTR2A
2 neuropeptide signaling pathway GO:0007218 9.77 TAC1 SSTR1 PYY
3 memory GO:0007613 9.73 SLC6A4 OXT HTR2A
4 chemical synaptic transmission GO:0007268 9.72 TAC1 SST HTR3A HTR2A HTR1A
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.69 SSTR1 HTR2A HTR1A
6 cell-cell signaling GO:0007267 9.65 TAC1 SST IFNA2 GHRH CGB3
7 vasoconstriction GO:0042310 9.61 SLC6A4 HTR1A
8 positive regulation of ossification GO:0045778 9.59 TAC1 OXT
9 oxidative demethylation GO:0070989 9.58 CYP3A4 CYP2D6
10 behavior GO:0007610 9.58 HTR2A HTR1A
11 positive regulation of renal sodium excretion GO:0035815 9.57 TAC1 OXT
12 sleep GO:0030431 9.55 OXT HTR2A
13 neurotransmitter catabolic process GO:0042135 9.54 MAOB MAOA
14 response to steroid hormone GO:0048545 9.54 SST OXT MAOB
15 dopamine catabolic process GO:0042420 9.52 MAOB MAOA
16 heterocycle metabolic process GO:0046483 9.49 CYP3A4 CYP2D6
17 drug catabolic process GO:0042737 9.48 CYP3A4 CYP2D6
18 monoterpenoid metabolic process GO:0016098 9.46 CYP3A4 CYP2D6
19 sperm ejaculation GO:0042713 9.43 SLC6A4 OXT
20 alkaloid catabolic process GO:0009822 9.4 CYP3A4 CYP2D6
21 response to food GO:0032094 9.33 OXT GHRH GAST
22 G protein-coupled receptor signaling pathway GO:0007186 9.32 TAC1 SSTR1 SST PYY OXT HTR2A
23 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A

Molecular functions related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.5 HTR3A HTR2A HTR1A
2 hormone activity GO:0005179 9.43 SST PYY OXT GHRH GAST CGB3
3 neuropeptide hormone activity GO:0005184 9.33 PYY OXT GHRH
4 primary amine oxidase activity GO:0008131 9.26 MAOB MAOA
5 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Serotonin Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....